Literature DB >> 30872336

Primary central nervous system plasmablastic lymphoma in an HIV-positive patient.

Ruben Rhoades1, Jerald Gong2, Neil Palmisiano1, Onder Alpdogan1.   

Abstract

Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. The neoplastic cells displayed a plasmacytoid appearance, with the expression of CD38 and CD138, and were positive for EBV by in situ hybridisation for EBV-encoded RNA. Systemic workup revealed the presence of Kaposi sarcoma, but no evidence of lymphoma. He is currently being treated with high-dose methotrexate, as well as antiretroviral therapy for his HIV infection, and has achieved a complete response. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  CNS cancer; HIV / AIDS; malignant and benign haematology

Mesh:

Substances:

Year:  2019        PMID: 30872336      PMCID: PMC6424190          DOI: 10.1136/bcr-2018-226755

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  28 in total

Review 1.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

2.  Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study.

Authors:  Philipp Schommers; Christoph Wyen; Marcus Hentrich; Daniel Gillor; Alexander Zoufaly; Bjoern Jensen; Johannes R Bogner; Jan Thoden; Jan C Wasmuth; Gerd Fätkenheuer; Christian Hoffmann
Journal:  AIDS       Date:  2013-03-13       Impact factor: 4.177

3.  Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience.

Authors:  Chiara Cattaneo; Alessandro Re; Marco Ungari; Annalisa Peli; Salvatore Casari; Filippo Castelnuovo; Simona Fisogni; Silvia Lonardi; Vilma Pellegrini; Marta Petullà; Fabio Facchetti; Giuseppe Rossi
Journal:  Leuk Lymphoma       Date:  2014-06-16

4.  Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.

Authors:  Jorge J Castillo; Eric S Winer; Dariusz Stachurski; Kimberly Perez; Melhem Jabbour; Cannon Milani; Gerald Colvin; James N Butera
Journal:  Leuk Lymphoma       Date:  2010-10-04

Review 5.  Primary CNS plasmablastic lymphoma: report of a case with CSF cytology, flow cytometry, radiology, histological correlation, and review of the literature.

Authors:  Paula A Rodriguez Urrego; Mark Smethurst; Mary Fowkes; Bruce Peterson; James Strauchen; Maoxin Wu; Arnold H Szporn; Hua Chen
Journal:  Diagn Cytopathol       Date:  2010-10-14       Impact factor: 1.582

6.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

Authors:  Tracy Batchelor; Kathryn Carson; Alison O'Neill; Stuart A Grossman; Jane Alavi; Pamela New; Fred Hochberg; Regina Priet
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

7.  Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.

Authors:  Ariela Noy; Shelly Y Lensing; Page C Moore; Neel Gupta; David Aboulafia; Richard Ambinder; Robert Baiocchi; Bruce J Dezube; David Henry; Lawrence Kaplan; Alexandra M Levine; Ronald Mitsuyasu; Lee Ratner; Erin Reid; Scot Remick; Joseph Sparano; Dimitrios Tzachanis; William Wachsman; Amy Chadburn
Journal:  Leuk Lymphoma       Date:  2015-12-16

8.  Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO.

Authors:  M Krogh-Jensen; F d'Amore; M K Jensen; B E Christensen; K Thorling; M Pedersen; P Johansen; A M Boesen; E Andersen
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976

Review 9.  HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.

Authors:  Jorge Castillo; Liron Pantanowitz; Bruce J Dezube
Journal:  Am J Hematol       Date:  2008-10       Impact factor: 10.047

10.  Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.

Authors:  Julie Morscio; Daan Dierickx; Jan Nijs; Gregor Verhoef; Emilie Bittoun; Xanne Vanoeteren; Iwona Wlodarska; Xavier Sagaert; Thomas Tousseyn
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

View more
  1 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.